

4/7/2020; Page 1

	Amitriptyline Hydrochloride 2%, Gabapentin 6%, Lidocaine Hydrochloride 0.5% Oral Mucoadhesive Rinse (Solution, 100 mL)	FIN	F 008 269
--	---	-----	-----------

## SUGGESTED FORMULATION

Ingredient Listing	Qty.	Unit	NDC #	Supplier	Lot Number	Expiry Date
Amitriptyline Hydrochloride, USP	2.000	g				
Gabapentin, USP	6.000	g				
Lidocaine Hydrochloride, USP	TBD					
Potassium Sorbate, NF	0.10	g				
Stevia Powder	0.10	g	<b>(</b>			
Menthol (Crystals) (Levorotatory) (Natural), USP	0.02	g				
Alcohol (95%), USP	5.0	mL		T		
NovaFilm™	30.0	mL	S	2		
Purified Water, USP	50.0	mL		•		
Purified Water, USP	q.s. to 100.0	mL				
Sodium Hydroxide 10% Solution	As required		R			

4



Suggested FormulaAmitriptyline Hydrochlo Oral Mucoadhesive Rins	ride 2%, Gabapentin 6%, Lidocaine Hydrochloride 0.5% e (Solution, 100 mL)	FIN	F 008 269			
SPECIAL PREPARATORY CONSIDE	RATIONS					
Ingredient-Specific Information						
Light Sensitive (protect from lig)	nt whenever possible): Amitriptyline Hydrochloride, G	ıbapentir	ı			
Hygroscopic (protect from moist	ure whenever possible): Stevia Powder					
Narrow Therapeutic Index	Lidocaine Hydrochloride					
Suggested Preparatory Guidelines	®					
Non-Sterile Preparatio	n Sterile Preparation					
	Fo account for processing error and pH testing considerat suggested to measure an additional <b>3 to 5%</b> of the required					
	This formula may contain one or more Active Pharmaceutinay be classified as hazardous, please refer & verify the containeoplastic and Other Hazardous Drugs in Healthcare S <b>Chapter &lt;800&gt; Hazardous Drugs – Handling in Health</b> Dublished February 1, 2016 in the First Supplement to USF delayed <b>official implementation date of December 31</b> <sup>st</sup> , 2016 February 1, 2016 in the appropriate facility of the prepared within the appropriate facility within USP 795 and USP 800, when handling hazardous departing the prepare this formula.	rrent NIC ettings, 2 care Setti 39-NF 3 019. ties unde es and pr ugs. Only	OSH list of 016. <b>General</b> <b>ings</b> was formally 4 and has a r adequate ocedures as stated y trained and b, such as but not			
	<ul> <li>limited to, lab coat, protective sleeves, gloves both inner and outer if applicable, dedicated shoe covers, hairnet, beard cover, eyewear, appropriate face mask, respirate and face shield, etc., where applicable must be worn at all times.</li> <li>If applicable, follow all required procedures for hazardous drug handling including bu not limited to procurement, transport, storage, preparation, dispensing, administration clean up (spills) &amp; disposal.</li> <li>If you are a registered 503B facility, please refer to all relevant guidance documents including but not limited to the Code of Federal Regulations (CFR), Guidance for Industry (GFIs) and Compliance Policy Guides (CPGs).</li> </ul>					
i						
]	Lidocaine Hydrochloride has a Narrow Therapeutic In	lex.				
	This procedure requires the use of very small quantities of and preparation techniques must be verified before dispense					



4/7/2020; Page 3

	Amitriptyline Hydrochloride 2%, Gabapentin 6%, Lidocaine Hydrochloride 0.5% Oral Mucoadhesive Rinse (Solution, 100 mL)	FIN	F 008 269
--	---	-----	-----------

# SUGGESTED PREPARATION (for 100 mL)

Weigh and / or measure the following ingredients when appropriate:

Ingredient Listing	Qty.	Unit	Multiplication factor <sup>(*)</sup> :	Processing Error	Qty. to measure
Amitriptyline Hydrochloride, USP §	2.000	g			
Gabapentin, USP §	6.000	g			
Lidocaine Hydrochloride, USP	TBD		<b>(R)</b>		
Potassium Sorbate, NF §	0.10	g			
Stevia Powder §	0.10	g	T T		
Menthol (Crystals) (Levorotatory) (Natural), USP	0.02	g	8		
Alcohol (95%), USP	5.0	mL			
NovaFilm <sup>TM</sup>	30.0	mL			
Purified Water, USP	50.0	mL			
Purified Water, USP	q.s. to 100.0	mL			
Sodium Hydroxide 10% Solution	As required				

§ Weigh / measure just prior to use.
\* Takes into account increased batch

\* Takes into account increased batch size conversions and density conversions, if required.



	Amitriptyline Hydrochloride 2%, Gabapentin 6%, Lidocaine Hydrochloride 0.5% Oral Mucoadhesive Rinse (Solution, 100 mL)	FIN	F 008 269
	Preparatory Instruction		
]	Ingredient quantification:		
1	A. Determine the potency of Lidocaine Hydrochloride based on the certificate of analysis:		
			100%
	MINUS		
	Water Content (from certificate of analysis)	-	%
	DIVIDED BY		100
	EQUALS		
	Quantity of water free Lidocaine Hydrochloride, in decimal	-	
	MULTIPLIED BY		
	Assay on anhydrous basis result (from certificate of analysis)	-	%
	DIVIDED BY		100
	EQUALS		
	i. Potency of Lidocaine Hydrochloride, in decimal	-	



	ggested ormula	Amitriptyline Hydrochloride 2%, Gabapentin 6%, Lidocaine Hydrochloride 0.5% Oral Mucoadhesive Rinse (Solution, 100 mL)	FIN	F 008 269
2.	Ingro	edient quantification:		
		Determine the quantity (in g) of Lidocaine Hydrochloride to make a 100 mL batch of Lid 0.5% Oral Rinse:	locaine	Hydrochloride
	C	Quantity of Lidocaine Hydrochloride required for 100 mL		0.500 g
	Ι	DIVIDED BY		
	F	Potency of Lidocaine Hydrochloride, in decimal (Step 1Ai)	_	
	E	EQUALS		
	i	. Quantity of Lidocaine Hydrochloride needed for 100 mL	-	g
	N	AULTIPLIED BY		
	F	Processing error adjustments (3 to 5%)	1	.03 to 1.05
	E	EQUALS		
	i	i. Quantity of Lidocaine Hydrochloride needed <i>plus</i> processing error adjustments	-	g
3.	Men	thol-solution preparation:		
	A. I	ncrementally add the Menthol (Crystals) (Levorotatory) (Natural) to the Alcohol (95%).		
	<u>S</u>	specification: Continuously mix until all solid particles have completely dissolved.		
	Ē	End result: Homogeneous liquid-like solution.		
4.	Powe	ler-liquid preparation:		
	A. (	Combine and triturate the following ingredients together to form a fine, homogeneous po	wder b	lend:
	-	Amitriptyline Hydrochloride Gabapentin Lidocaine Hydrochloride (amount determined in Step 2Aii) Potassium Sorbate Stevia Powder		
	B. I	Levigate the fine, homogeneous powder blend (Step 4A) with the homogeneous liquid-lil	ke solu	tion (Step 3A).
	Ē	End result: Homogeneous liquid-like dispersion.		



	Amitriptyline Hydrochloride 2%, Gabapentin 6%, Lidocaine Hydrochloride 0.5% Oral Mucoadhesive Rinse (Solution, 100 mL)	FIN	F 008 269				
5.	Powder-liquid to medium incorporation:						
	A. In the given order, sequentially add the following ingredients to the Purified Water (50.0 error adjustments):	mL pl	us processing				
	-Homogenous liquid-like dispersion (Step 4B) -NovaFilm <sup>™</sup>						
	Specifications: Continuously mix until all the particles have been dissolved.						
	End result: Homogeneous liquid-like solution.						
6.	pH testing:						
	A. Draw an appropriate amount of the mixture (Step 5A).						
	B. Test the pH of the sample. It should lie between 6.0 and 7.0.						
	C. If the pH < 6.0, carefully add, in a dropwise fashion, the Sodium Hydroxide 10% Solution	n to the	e mixture:				
	<ol> <li>Draw and transfer 1 or 2 drops of the Sodium Hydroxide 10% Solution to the mixtur</li> <li>Stir for at least 5 minutes to evenly disperse the Sodium Hydroxide 10% Solution.</li> <li>Re-test the pH.</li> </ol>						
	4. Continue to add the Sodium Hydroxide 10% Solution until the pH of 6.0 to 7.0 is ob	tained.					
	<b>IMPORTANT</b> : Do not allow the pH to rise above 7.0.						
7.	Filling to volume:						
	A. Add additional Purified Water to the above mixture to fill to the required batch size (100 error adjustments).	0 mL j	plus processing				
	Specifications: Continuously mix.						
	End result: Homogeneous liquid-like solution.						
8.	Product transfer						
	Transfer the final product into the specified dispensing container (see "Packaging requirement	ts").					



4/7/2020; Page 7

	•. •					4/7/2020; Page
		otyline Hydrochloride 2%, Gabapentin 6%, Li ucoadhesive Rinse (Solution, 100 mL)	locaine	e Hydrochloride 0.5%	FIN	F 008 269
GGESTED PR	ESE	NTATION				
Estimated Beyond-Use Date 14 days, refrigerated, as per USP Tightly closed, light- USP To be administered device.		- To be administered				
	1	Use as directed. Do not exceed prescribed dose.	6	Do not take with alcoho or other CNS depressant		p aids, tranquilize
	2	Keep out of reach of children.	7	Cap tightly after use.		
Auxiliary Labels	3	Consult your health care practitioner if any other prescription or over-the-counter medications are currently being used or are prescribed for future use.	Q	For local (oral) use only.		
	4	Protect from light.	9	To be used as a m swallowed.	outh	rinse; not to
	5	Keep refrigerated ( $2^{\circ}C - 8^{\circ}C$ ). Do no freeze.	10	May impair mental and care when operating a ca		
Pharmacist Instructions	Ad	<ul> <li>PORTANT: - Non-sterile preparation, do         <ul> <li>Use of this formula is intend</li> <li>d any auxiliary labels specific to the API to the</li> </ul> </li> <li>PORTANT: - Small batch is prepared due to         <ul> <li>Limits as to the total amount</li> <li>You should not apply this problistered, deep wounds, or lar</li> <li>Continued application of this patient accordingly.</li> </ul> </li> <li>PORTANT: DRUG-DRUG INTERAC</li> </ul>	ed for e dispe o inhere of prod duct to ge area produc	local treatment and not f ensing container as deemed ent potential of systemic to luct used should be establis o open wounds, areas of ski as.	for sys I neces axicity. Thed by In that side ef	stemic treatment ssary. y a physician. are damaged or

Patient

Contact your pharmacist in the event of adverse reactions.

**Instructions IMPORTANT:** - The quantity of API administered is directly dependent on the quantity of product applied.



4/7/2020; Page 8

	And Amitriptyline Hydrochloride 2%, Gabapentin 6%, Lidocaine Hydrochloride 0.5% Formula Oral Mucoadhesive Rinse (Solution, 100 mL)	FIN	F 008 269					
FER	ENCES							
1.	Solutions. In: Allen, LV, Jr. <i>The Art, Science and Technology of Pharmaceutical Compounding Fifth Edition.</i> American Pharmaceutical Association; 2016: 263.							
2.	Amitriptyline Hydrochloride. In: Sweetman SC, ed. <i>Martindale: The Complete Drug Reference, 36<sup>th</sup> Edition</i> . London, England: The Pharmaceutical Press; 2009: 376.							
3.	Gabapentin. In: Sweetman SC, ed. <i>Martindale: The Complete Drug Reference, 36<sup>th</sup> Edition</i> . London, England: The Pharmaceutical Press; 2009: 482.							
4.	Lidocaine Hydrochloride. In: Sweetman SC, ed. <i>Martindale: The Complete Drug Reference</i> England: The Pharmaceutical Press; 2009: 1862.	e, 36 <sup>th</sup> Ea	ition. London,					
5.	Amitriptyline (Monograph). In: O'Neil MJ. <i>The Merck Index 15<sup>th</sup> Edition</i> . Whitehouse Station, NJ: Merck & Co, Inc.; 2013: Monograph #483.							
6.	Gabapentin. In: O'Neil MJ. <i>The Merck Index 15<sup>th</sup> Edition</i> . Whitehouse Station, NJ: Merck & Co, Inc.; 2013: Monograph #4348.							
7.	Lidocaine (Monograph). In: O'Neil MJ. <i>The Merck Index 15<sup>th</sup> Edition</i> . Whitehouse Station, NJ: Merck & Co, Inc.; 2013: Monograph #5535.							
8.	Amitriptyline Hydrochloride. In: Trissel LA. <i>Trissel's Stability of Compounded Formulati</i> Pharmaceutical Association; 2012: 33.	ons, 5 <sup>th</sup> Ed	lition. American					
9.	Gabapentin. In: Trissel LA. Trissel's Stability of Compounded Formulations, 5th Edition. A Association; 2012: 221.	merican 1	Pharmaceutical					
10.	Lidocaine Hydrochloride. In: Trissel LA. <i>Trissel's Stability of Compounded Formulations</i> Pharmaceutical Association; 2012: 288.	5 <sup>th</sup> Editio	n. American					
11.	Amitriptyline Hydrochoride (Monograph). <i>United States Pharmacopeia XLII / National Fu</i> US Pharmacopeial Convention, Inc. 2019: 259.	ormulary	37. Rockville, MD					
12.	Gabapentin (Monograph). <i>United States Pharmacopeia XLII / National Formulary 37</i> . Ropharmacopeial Convention, Inc. 2019: 2010.	Gabapentin (Monograph). United States Pharmacopeia XLII / National Formulary 37. Rockville, MD. US Pharmacopeial Convention, Inc. 2019: 2010.						
13.	Lidocaine Hydrochloride (Monograph). United States Pharmacopeia XLII / National Form Pharmacopeial Convention, Inc. 2019: 2569.	Lidocaine Hydrochloride (Monograph). United States Pharmacopeia XLII / National Formulary 37. Rockville, MD. US Pharmacopeial Convention, Inc. 2019: 2569.						
14.	USP <795>. United States Pharmacopeia XLII / National Formulary 37. Rockville, MD. Convention, Inc. 2019: 6951.	JS Pharm	acopeial					

DISCLAIMER: THIS DOCUMENT IS COPYRIGHT© 2020 MEDISCA PHARMACEUTIQUE INC. MEDISCA NETWORK INC., HEREBY REFERRED TO AS 'THE NETWORK', HAS PROVIDED THE FORMULA AND INSTRUCTIONS ABOVE AS A MODEL FOR EDUCATIONAL PURPOSES ONLY ON THE BASIS OF THE RECOGNIZED COMPENDIA AND TEXTS REFERENCED AT THE END OF THIS DOCUMENT. THE NETWORK TAKES NO RESPONSIBILITY FOR THE VALIDITY, SCHEDULING OR ACCURACY OF THIS INFORMATION OR FOR ITS SAFETY OR EFFECTIVENESS, NOR FOR ANY USE THEREOF, WHICH IS AT THE SOLE RISK OF THE LICENSED PHARMACIST OR OTHER APPROPRIATELY STATE LICENSED PROFESSIONAL. ADJUSTMENTS MAY BE NEEDED TO MEET SPECIFIC PATIENT NEEDS AND IN ACCORDANCE WITH A LICENSED PRESCRIBER'S PRESCRIPTION. THE PHARMACIST OR OTHER APPROPRIATELY STATE LICENSED PROFESSIONAL MUST EMPLOY APPROPRIATE TESTS TO DETERMINE THE STABILITY OF THIS SUGGESTED FORMULA. THE NETWORK CANNOT BE HELD LIABLE TO ANY PERSON OR ENTITY CONCERNING CLAIMS, LOSS, OR DAMAGE CAUSED BY, OR ALLEGED TO BE CAUSED BY, DIRECTLY OR INDIRECTLY, THE USE OR MISUSE OF THE INFORMATION CONTAINED IN THIS SUGGESTED FORMULA. IN ALL CASES IT IS THE RESPONSIBILITY OF THE LICENSED PHARMACIST OR OTHER APPROPRIATELY STATE LICENSED PROFESSIONAL TO KNOW THE LAW, TO COMPOUND ANY FINISHED PRODUCT AND TO DISPENSE THESE PRODUCTS IN ACCORDANCE WITH FEDERAL AND STATE LAW. MEDISCA NETWORK INC. MAKES NO WARRANTIES WITH RESPECT TO INFRINGEMENT OR NON-INFRINGEMENT BY THE FORMULA OF ANY PATENT OR OTHER INTELLECTUAL PROPERTY OF ANY OTHER PARTY, AND IT IS THE RESPONSIBILITY OF THE PHARMACIST OR OTHER APPROPRIATELY STATE LICENSED PROFESSIONAL TO INVESTIGATE AND DETERMINE ANY SUCH ISSUE.